Retatrutide Information

Retatrutide (also known by its development code LY-3437943) is an experimental drug being developed primarily for the treatment of obesity and Type 2 diabetes. It is not yet approved by the FDA or other regulatory bodies and is currently in Phase 3 clinical trials.

It is considered a major advancement because of its triple-action mechanism.

How Retatrutide Works: Triple-Action Agonist

Retatrutide is a triple hormone receptor agonist. This means it is a single molecule that mimics the actions of three different natural hormones in the body that are involved in regulating blood sugar and appetite:

1- Glucagon-like peptide-1 (GLP-1) Receptor Agonist:

• Action: Slows down gastric emptying (how quickly food leaves the stomach), which makes you feel fuller for longer.
• Effect: Suppresses appetite and helps regulate blood glucose by stimulating insulin release in a glucose-dependent manner.

2- Glucose-dependent insulinotropic polypeptide (GIP) Receptor Agonist:

• Action: Also enhances glucose-dependent insulin secretion and helps the body process fat (lipid metabolism).
• Effect: Further helps to lower blood sugar and contributes to reducing appetite and overall energy balance.

3- Glucagon (GCG) Receptor Agonist:

• Action: Glucagon primarily raises blood sugar, but its agonism in the context of Retatrutide's triple action promotes the breakdown of stored fat.
• Effect: Stimulates the body to burn fat for energy (lipolysis) and increases overall energy expenditure (calorie burning).

By hitting all three pathways, Retatrutide is designed to provide a comprehensive effect, integrating signals that reduce appetite, improve insulin sensitivity, and promote energy expenditure concurrently.